

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-18. (cancelled)

Claim 19. (withdrawn) An isolated peptide comprising ND2.1 (SEQ ID NO:7) wherein said peptide exhibits interaction with a Src unique domain.

Claim 20. (withdrawn) The isolated peptide as in claim 19 wherein said interaction is anchoring Src to a NMDAR complex.

Claim 21. (withdrawn) The isolated peptide as in claim 20 wherein said anchoring permits upregulation of NMDAR activity through Src.

Claims 22-49. (cancelled)

Claim 50. (Previously Presented) A pharmaceutical composition for inhibiting N-methyl-D-aspartate receptor (NMDAR) interaction with non-receptor tyrosine kinase Src in cells; said pharmaceutical composition consisting of SEQ ID NO:2 combined with a pharmaceutically acceptable solution.

Claim 51. (Previously Presented) A pharmaceutical composition for inhibiting non-receptor tyrosine kinase Src in cells expressing non-receptor tyrosine kinase Src; said pharmaceutical composition consisting of SEQ ID NO:2 combined with a pharmaceutically acceptable solution.

Claim 52. (Previously Presented) A pharmaceutical composition for inhibiting NMDAR interaction with non-receptor tyrosine kinase Src in cells from a tissue selected from the group consisting of central nervous system tissue and peripheral nervous system tissue; said pharmaceutical composition consisting of SEQ ID NO:2 combined with a pharmaceutically acceptable solution.

Claim 53. (Previously Presented) A pharmaceutical composition for inhibiting non-receptor tyrosine kinase Src in cells expressing non-receptor tyrosine kinase Src and obtained from a tissue selected from the group consisting of central nervous system,

peripheral nervous system, heart, intestine, kidney, liver, lung, pancreas, skeletal muscle, spleen, testis, bone, skin and brain; said pharmaceutical composition consisting of SEQ ID NO:2 combined with a pharmaceutically acceptable solution.

Claim 54. (Currently Amended) A method for inhibiting N-methyl-D-aspartate receptor (NMDAR) interaction with non-receptor tyrosine kinase Src in cells comprising:

providing the pharmaceutical composition of claim 50; and administering said pharmaceutical composition to said cells in an amount effective to achieve inhibition of said NMDAR interaction with said non-receptor tyrosine kinase Src in said cells wherein said inhibition ameliorates a disease or condition related to NADH dehydrogenase subunit 2 (ND2)dependent NMDAR signaling.

Claim 55. (Currently Amended) A method for inhibiting non-receptor tyrosine kinase Src phosphorylation of NMDAR in cells expressing non-receptor tyrosine kinase Src comprising:

providing the pharmaceutical composition of claim 51; and administering said composition to said cells in an amount effective to achieve inhibition of said non-receptor tyrosine kinase Src in said cells.

Claim 56. (Currently Amended) A method for inhibiting N-methyl-D-aspartate receptor (NMDAR) interaction with non-receptor tyrosine kinase Src in cells comprising:

providing the pharmaceutical composition of claim 52; and administering said pharmaceutical composition to said cells in an amount effective to achieve inhibition of said NMDAR interaction with said non-receptor tyrosine kinase Src in said cells wherein said inhibition ameliorates a disease or condition related to NADH dehydrogenase subunit 2 (ND2)dependent NMDAR signaling.

Claim 57. (Currently Amended) A method for inhibiting non-receptor tyrosine kinase Src phosphorylation of NMDAR in cells expressing non-receptor tyrosine kinase Src comprising:

providing the pharmaceutical composition of claim 53; and administering said composition to said cells in an amount effective to achieve inhibition of said non-receptor tyrosine kinase Src in said cells.